DOCSLIB.ORG

Androgen Receptor Antagonism Drives Efficacy of CYP17 Inhibitors in CRPC

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Androgen Receptor Antagonism Drives Efficacy of CYP17 Inhibitors in CRPC Supplemental Material Androgen Receptor Antagonism Drives Efficacy of CYP17 Inhibitors in CRPC John D. Norris1#, Stephanie J. Ellison1#, Jennifer G. Baker1, David B. Stagg1, Suzanne E. Wardell1, Sunghee Park1, Holly M. Alley1, Robert M. Baldi1, Alexander Yllanes1, Kaitlyn J. Andreano, James P. Stice1, Scott A. Lawrence1, Joel R. Eisner2, Douglas K. Price3, William R. Moore2, William D. Figg3, and Donald P. McDonnell1* 1 Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710 2 Innocrin Pharmaceuticals, Durham, NC 27703 3 Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892 *To whom correspondence should be addressed: Donald P. McDonnell Email: [email protected] Phone: 919-684-6035 Fax: 919-691-7139 # Contributed equally to this work. 1 Supplemental Tables and Figures GR PR MR Enzalutamide > 20 μM 2.7 E-06 > 20 μM Seviteronel > 20 μM 9.0 E-06 > 20 μM Galeterone > 20 μM 1.9 E-06 > 20 μM Abiraterone > 20 μM 2.1 E-07 > 20 μM RU 486 7.9 E-09 1.0 E-11 ND Spironolactone ND ND 3.2 E-09 Supplemental Table 1. Effects of CYP17 inhibitors on transcriptional activation of GR, PR, and MR. CV1 cells were transfected with MMTV-luc, Renilla-luc, and either glucocorticoid (GR), progesterone (PR), or mineralocorticoid (MR) receptor constructs. Cells were then treated for 24 hours with increasing doses of the indicated antagonists in the presence of 0.1 nM of appropriate agonist: GR, dexamethasone; PR, R5020; MR, aldosterone. Luciferase values were measured and IC50 values are shown in the table. ND, not determined. 2 A B PSA-Luc CV1 VCAP LNCaP AR β-actin + Testosterone Supplemental Figure 1. Effects of CYP17 inhibitors on PSA-Luc (A) Protein extracts from CV1 cells transfected with wt-AR expression vector, MMTV-luc, and Renilla-luc were analyzed for AR expression using anti-AR antibody (N20). Protein extracts from VCAP and LNCaP cells are included as controls for endogenous AR expression. β-actin is included as a loading control. (B) CV1 cells were transfected with PSA-luc and treated for 24 hours with the indicated ligand in the presence of 1.0 nM testosterone. Cells were lysed and assayed for luciferase activity. Error is reported as SD from a representative experiment performed in triplicate. 3 A B 80000 150000 No Competitor No Competitor Enz, 0.2 μM Sevi, 3.0 μM 60000 Enz, 0.6 μM Sevi, 10 μM s 100000 s t i t i Enz, 2.0 μM n Sevi, 30 μM n U U t t 40000 gh i gh i L L 50000 20000 0 0 -14 -12 -10 -8 -6 -14 -12 -10 -8 -6 Log [Ligand] Log [Ligand] C D 80000 No Competitor 80000 No Competitor Gal, 1.0 μM Abi, 3.0 μM 60000 Gal, 3.0 μM 60000 Abi, 10 μM s s t t i Gal, 10 μM i Abi, 30 μM n n U U t 40000 t 40000 gh gh i i L L 20000 20000 0 0 -14 -12 -10 -8 -6 -14 -12 -10 -8 -6 Log [Ligand] Log [Ligand] Supplemental Figure 2. CYP17 inhibitors are competitive AR ligands. CV1 cells were transfected with wt-AR, MMTV-luc, and Renilla-luc, followed by treatment with increasing concentrations of R1881 and the indicated dose of competitor ligand (A) enzalutamide, (B) seviteronel, (C) galeterone, or (D) abiraterone. Luciferase activity was measured after 24 hour incubation. Error bars indicate SD of triplicate samples of a representative experiment performed in duplicate. Shifts in EC50 but not Vmax values indicate competitive antagonism. 4 KLK3 NKX3-1 25 10 s l 20 e 8 v Le 15 Veh A 6 Veh RN 10 T e 4 T v i t a l 5 e 2 R 0 0 i l i t i l i t h c z a r h c z a r Ve Bi En Sev G Ab O Ve Bi En Sev G Ab O Supplemental Figure 3. KLK3 and NKX3.1 expression in LNCaP cells. LNCaP cells were treated with vehicle, 10 nM testosterone (T), and 10 µM of the indicated ligand for 24 hours. Real-time PCR was performed to assess KLK3 and NKX3.1 mRNA expression. Error bars represent the SD from triplicate samples of a representative experiment performed in triplicate. 5 100 80 G1 S 60 G2/M 40 Percentage of Cells 20 0 Veh T Enz Sevi Gal Abi Ort + T Supplemental Figure 4. CYP17 inhibitors prevent entry of prostate cancer cells into S phase. LNCaP cells were treated with vehicle, 10 nM testosterone (T), and 10 µM of the indicated ligand for 24 hours. DNA was stained with propidium iodide and cell cycle analysis was performed using flow cytometry. Data are presented as percentage of cells in G1, S, or G2/M phase. Representative data are shown from an experiment performed in triplicate. 6 DU145 20000 Veh Enz 15000 Sevi U Gal F 10000 R Abi 5000 0 0 2 4 6 Days of Treatment Supplemental Figure 5. CYP17 inhibitors have minimal effects on AR-negative DU145 cell growth. DU145 cells were treated with 10 µM of the indicated compound and analyzed for cell growth by Hoechst dye (DNA content) on 1, 3, and 5 days post-treatment. Error bars represent SD of triplicate samples of a representative experiment performed in duplicate. 7 KLK3 NKX3-1 15 8 s s l l e e v v 6 Le Le 10 A A Veh Veh 4 RN RN e e T T v v i i t t 5 a a l l 2 e e R R 0 0 i l i t i l i t h c z a r h c z a r Ve Bi En Sev G Ab O Ve Bi En Sev G Ab O Supplemental Figure 6. KLK3 and NKX3.1 expression in LNCaP-AR cells. LNCaP-AR cells were treated with vehicle, 1.0 nM testosterone (T), and 10 µM of the indicated ligand for 24 hours. Real-time PCR was performed to assess KLK3 and NKX3.1 mRNA expression. Error bars represent the SD from triplicate samples of a representative experiment performed in triplicate. 8 A B WT T877A 40000 Enz 25000 Enz Bic Bic 20000 30000 Sevi Sevi s s t t i Gal i n n 15000 Gal U U t 20000 Abi t Abi gh gh i i 10000 L L 10000 5000 0 0 -8 -7 -6 -5 -4 -8 -7 -6 -5 -4 Log [Ligand] Log [Ligand] C D W741C F876L 40000 20000 Enz Enz Bic Bic 30000 15000 Sevi Sevi s s t t i i n Gal n Gal U U t 20000 Abi t 10000 Abi gh gh i i L L 10000 5000 0 0 -8 -7 -6 -5 -4 -8 -7 -6 -5 -4 Log [Ligand] Log [Ligand] Supplemental Figure 7. CYP17 inhibitors do not display agonist activity on wild-type or mutant AR. CV1 cells were transfected with MMTV-luc, Renilla-luc, and either (A) wt-AR, (B) AR-T877A, (C) AR-W741C, or (D) AR-F876L expression plasmids. Cells were then treated for 24 hours with increasing doses of indicated ligands in the absence of R1881 and luciferase activity was measured. Error bars represent SD of triplicate samples for a representative experiment performed in duplicate. 9 KLK3 NKX3-1 80 8 s s l l e e v v 60 6 Le Le A A Veh Veh 40 4 RN RN e e T T v v i i t t a a l l 20 2 e e R R 0 0 i l i t i l i t h c z a r h c z a r Ve Bi En Sev G Ab O Ve Bi En Sev G Ab O Supplemental Figure 8. KLK3 and NKX3.1 expression in LNCaP AR-F876L cells. LNCaP AR F876L cells were treated with vehicle, 3.0 nM testosterone (T), and 10 µM of the indicated ligand for 24 hours. Real-time PCR was performed to assess KLK3 and NKX3.1 mRNA expression. Error bars represent the SD from triplicate samples of a representative experiment performed in triplicate. 10 A LNCaP-AR B LNCaP-F876L 16000 18000 16000 14000 14000 U U F 12000 F R R 12000 10000 10000 8000 8000 -16 -14 -12 -10 -8 -16 -14 -12 -10 -8 Log [Ligand] Log [Ligand] Supplemental Figure 9. R1881 promotes growth of AR overexpression and enzalutamide- resistant CRPC models. (A) LNCaP-AR or (B) LNCaP-F876L cells were treated with increasing doses of R1881. Following seven-day incubation, cell growth was measured by assessing DNA content using Hoechst dye. Error bars represent SD of triplicate samples from a representative experiment performed in duplicate. 11 A LNCaP 1000 Veh Sevi, 15 mg/kg r ) 800 o 3 Sevi, 50 mg/kg m m u Sevi, 100 mg/kg T (m 600 e m age r 400 e olu v a V A 200 0 0 7 14 21 28 Days of Treatment B KLK2 SGK1 1.5 1.5 n n o o i i ss ss e e r r 1.0 1.0 p p x x E E ed ed z z li li a a 0.5 0.5 m m r r o o N N P < 0.01 P < 0.01 0.0 0.0 e l e l Vehicl Vehicl Seviterone Seviterone TMPRSS2 DBI 1.1 1.5 n n o o i i 1.0 ss ss e e r r 1.0 p p x x 0.9 E E ed ed z z 0.8 li li a a 0.5 m m r r o o 0.7 N N P < 0.05 P < 0.05 0.6 0.0 e l e l Vehicl Vehicl Seviterone Seviterone Supplemental Figure 10.
Load more

Recommended publications
  • Galeterone for the Treatment of Castration- Resistant Prostate Cancer Bruce Montgomery1, Mario A
    Published OnlineFirst November 2, 2015; DOI: 10.1158/1078-0432.CCR-15-1432 Cancer Therapy: Clinical Clinical Cancer Research Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration- Resistant Prostate Cancer Bruce Montgomery1, Mario A. Eisenberger2, Matthew B. Rettig3, Franklin Chu4, Roberto Pili5, Joseph J. Stephenson6, Nicholas J. Vogelzang7, Alan J. Koletsky8, Luke T. Nordquist9, William J. Edenfield10, Khalid Mamlouk11, Karen J. Ferrante11, and Mary-Ellen Taplin12 Abstract Purpose: Galeterone is a selective, multitargeted agent that Results: In ARMOR1, across all doses, 49.0% (24/49) achieved a inhibits CYP17, antagonizes the androgen receptor (AR), and 30% decline in prostate-specific antigen (PSA; PSA30) and reduces AR expression in prostate cancer cells by causing an 22.4% (11/49) demonstrated a 50% PSA decline (PSA50). In increase in AR protein degradation. These open-label phase I ARMOR2 part 1, across all doses, PSA30 was 64.0% (16/25) and and II studies [Androgen Receptor Modulation Optimized PSA50 was 48.0% (12/25). In the 2,550-mg dose cohort, PSA30 for Response-1 (ARMOR1) and ARMOR2 part 1] evaluated was 72.7% (8/11) and PSA50 was 54.5% (6/11). Galeterone was the efficacy and safety of galeterone in patients with treat- well tolerated; the most common adverse events were fatigue, ment-naive nonmetastatic or metastatic castration-resistant increased liver enzymes, gastrointestinal events, and pruritus. Most prostate cancer (CRPC) and established a dose for further were mild or moderate in severity and required no action and there study. were no apparent mineralocorticoid excess (AME) events.
    [Show full text]
  • WO 2018/111890 Al 21 June 2018 (21.06.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/111890 Al 21 June 2018 (21.06.2018) W !P O PCT (51) International Patent Classification: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, C07K 16/28 (2006.01) A61K 31/4166 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 59/595 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/US20 17/065841 Declarations under Rule 4.17: (22) International Filing Date: — as to applicant's entitlement to apply for and be granted a 12 December 2017 (12.12.2017) patent (Rule 4.1 7(H)) — as to the applicant's entitlement to claim the priority of the (25) Filing Language: English earlier application (Rule 4.17(Hi)) (26) Publication Langi English — of inventorship (Rule 4.1 7(iv)) (30) Priority Data: Published: 62/433,158 12 December 2016 (12.12.2016) US — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (71) Applicant (for all designated States except AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, P T RO, RS, SE, SI, SK, SM, TR): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Download Product Insert (PDF)
    Product Information Galeterone Item No. 17586 N CAS Registry No.: 851983-85-2 Formal Name: 17-(1H-benzimidazol-1-yl)-androsta- 5,16-dien-3β-ol N Synonym: TOK-001 MF: C26H32N2O FW: 388.6 H Purity: ≥98% H H Stability: ≥2 years at -20°C Supplied as: A crystalline solid HO Laboratory Procedures For long term storage, we suggest that galeterone be stored as supplied at -20°C. It should be stable for at least two years. Galeterone is supplied as a crystalline solid. A stock solution may be made by dissolving the galeterone in the solvent of choice. Galeterone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of galeterone in ethanol and DMSO is approximately 20 mg/ml and approximately 30 mg/ml in DMF. Galeterone is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, galeterone should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Galeterone has a solubility of approximately 0.2 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. The cytochrome P450 (CYP) isoform CYP17 is also known as steroid 17α-hydroxylase/17,20 lyase because it catalyzes both 17α-hydroxylase and 17,20 lyase reactions in the synthesis of steroids, including androgens, estrogens, glucocorticoids, 1 and mineralocorticoids. Galeterone is a CYP17 inhibitor (IC50 = 300 nM) that has been shown to competitively block synthetic androgen binding (EC50 = 845 nM) and to antagonize the androgen receptor in transcriptional activation 2 assays.
    [Show full text]
  • Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope
    cancers Review Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope Sirin Saranyutanon 1,2, Sanjeev Kumar Srivastava 1,2,*, Sachin Pai 3, Seema Singh 1,2,4 and Ajay Pratap Singh 1,2,4,* 1 Department of Pathology, College of Medicine, University of South Alabama, Mobile, AL 36617, USA; [email protected] (S.S.); [email protected] (S.S.) 2 Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA 3 Department of Medical Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA; [email protected] 4 Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA * Correspondence: [email protected] (S.K.S.); [email protected] (A.P.S.); Tel.: +1-251-445-9874 (S.K.S.); +1-251-445-9843 (A.P.S.) Received: 4 November 2019; Accepted: 18 December 2019; Published: 23 December 2019 Abstract: Prostate cancer is the mostly commonly diagnosed non-cutaneous malignancy and the second leading cause of cancer-related death affecting men in the United States. Moreover, it disproportionately affects the men of African origin, who exhibit significantly greater incidence and mortality as compared to the men of European origin. Since androgens play an important role in the growth of normal prostate and prostate tumors, targeting of androgen signaling has remained a mainstay for the treatment of aggressive prostate cancer. Over the years, multiple approaches have been evaluated to effectively target the androgen signaling pathway that include direct targeting of the androgens, androgen receptor (AR), AR co-regulators or other alternate mechanisms that impact the outcome of androgen signaling.
    [Show full text]
  • ESMO E-Learning Metastatic Castrate-Resistant Prostate Cancer
    METASTATIC CASTRATE- RESISTANT PROSTATE CANCER TREATMENT (MCRPC) Fabricio Racca GU, CNS and Sarcoma Programme, Oncology Department Vall d’Hebron University Hospital, Barcelona, Spain AGENDA First-line treatment in mCRPC patients: Standard of Care Androgen Biosynthesis Inhibitors (ABIs) Second generation antiandrogens Docetaxel Radium 223 Novel hormonal therapies Immunotherapy Targeted therapies Failed trials Conclusions Siegel RL, et al., CA Cancer J Clin 2017;67:7–30. © 2017 American Cancer Society. With permission from John Wiley and Sons. SINCE 2010 A PLETHORA OF NEW TRIALS HAVE SHOWN BENEFIT IN MCRPC Trial / agent approved Disease state Comparator Hazard ratio P value IMPACT Chemo-näive CRPC Placebo 0.77 0.032 (Provenge vaccine) 2010 COU-AA-302 Placebo Chemo-naïve CRPC UK UK (Abiraterone acetate) 2012 Prednisone Pre-docetaxel ALSYPMCA (Radium 223) 2013 BSC 0.74 <0.00046 CRPC PREVAIL (Enzalutamide) 2014 Chemo-naïve CRPC Placebo 0.71 <0.0001 Mitoxantrone TAX327 (Docetaxel) 2004 Chemo-naïve CRPC 0.76 0.009 Prednisone Mitoxantrone TROPIC (Cabazitaxel) 2010 Post-docetaxel CRPC 0.70 <0.0001 Prednisone COU-AA-301 Post-docetaxel Placebo 0.65 <0.0001 (Abiraterone acetate) 2010 CRPC Prednisone Post-docetaxel ALSYPMCA (Radium 223) 2013 BSC 0.71 <0.00046 CRPC Post-docetaxel AFFIRM (Enzalutamide) 2012 BSC 0.63 <0.0001 CRPC ANDROGEN BIOSYNTHESIS INHIBITORS (ABIS) ABIRATERONE ACETATE + PREDNISONE Cholesterol Desmolase Renin Deoxy- Pregnenolone Progesterone Corticosterone Aldosterone corticosterone CYP17 17α-hydroxylaseX 11β-Hydroxylase ACTH 17α-OH- 17α –OH- 11-Deoxy- Cortisol pregnenolone progesterone cortisol CYP17 C17,20X-lyase 5α-reductase DHEA Androstenedione Testosterone DHT CYP19: aromatase Estradiol Adapted from Attard G, et al., J Clin Oncol 26(28), 2008: 4563-71.
    [Show full text]
  • Development of Combination Therapy for Prostate Cancer
    DEVELOPMENT OF COMBINATION THERAPY FOR PROSTATE CANCER A Dissertation Presented to the Faculty of the Weill Cornell Graduate School of Medical Sciences in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Alexander R. Root July 2017 © 2017 Weill Cornell Graduate School of Medical Sciences ALL RIGHTS RESERVED DEVELOPMENT OF COMBINATION THERAPY FOR PROSTATE CANCER Alexander R. Root, Ph.D. Cornell University 2017 There is an unmet need in prostate cancer for effective therapies to prevent the emergence of resistance. Combinations of small molecules targeting key pathways are a promising strategy. I investigated how populations of the early metastatic prostate cancer cell line LNCaP respond at the proteomic and pheno- typic levels to six clinically-relevant, one-drug treatments and their 15 pairs of two-drug combinations, administered simultaneously to treatment-naive cells. After 24 hours of drug addition for all 21 drug treatments I measured 52 total- proteins by selected-reaction monitoring mass-spectrometry based proteomics (SRM), 20 phospho-proteins, and 50 total-proteins by reverse-phase protein ar- rays (RPPA). I measured phenotypic effects on cell proliferation and apoptosis in all conditions using phase-contrast and fluorescence microscopy. Network analysis identified (phospho)-proteins with large responses to drug treatments that are druggable with FDA-approved drugs or have nearest-neighbors that are druggable. A total of ten drugs targeting these nearest responder (phospho)-proteins were tested in single, double, and triple combinations. I found that 7 out of 10 triple combinations co-targeting androgen receptor and PI3K pathways were no more effective than the two-drug combination at the doses tested: PRKC (en- zastaurin), MAPK (losmapimod), STAT3 (napabucasin), HDAC (panobinostat), SRC (saracatinib), casein kinase (silmitasertib), MAPK (ulixertinib).
    [Show full text]
  • Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: a Review of Clinical Effectiveness and Cost- Effectiveness
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost- Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: June 6, 2019 Report Length: 30 Pages Authors: Khai Tran, Suzanne McCormack Cite As: Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness. Ottawa: CADTH; 2019 Jun. (CADTH rapid response report: summary with critical appraisal). ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect.
    [Show full text]
  • ( 12 ) United States Patent
    US010314797B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 314 ,797 B2 Narayanan et al. ( 45 ) Date of Patent : * Jun . 11, 2019 ( 54 ) SELECTIVE ANDROGEN RECEPTOR ( 56 ) References Cited DEGRADER (SARD ) LIGANDS AND METHODS OF USE THEREOF U . S . PATENT DOCUMENTS 5 ,480 ,656 A 1 / 1996 Okada et al . (71 ) Applicant: University of Tennessee Research 5 ,575 , 987 A 11/ 1996 Kamei et al . Foundation , Knoxville , TN (US ) 5 ,631 , 020 A 5 / 1997 Okada et al. 5 , 643 ,607 A 7 / 1997 Okada et al. 5 ,716 ,640 A 2 / 1998 Kamei et al. ( 72 ) Inventors : Ramesh Narayanan , Cordova , TN 5 , 814 ,342 A 9 / 1998 Okada et al . (US ) ; Duane D . Miller , Collierville , 6 ,036 , 976 A 3 / 2000 Takechi et al . TN (US ) ; Thamarai Ponnusamy , 7 , 118 , 552 B2 10 / 2006 Shaw et al . Memphis , TN (US ); Dong - Jin Hwang, 7 , 220 , 247 B25 / 2007 Shaw et al . 7 ,500 , 964 B23 / 2009 Shaw et al . Arlington , TN (US ) ; Yali He, 9 ,815 , 776 B2 * 11 / 2017 Narayanan . .. .. C07C 255 /60 Germantown , TN (US ) 9 , 834 , 507 B2 * 12 / 2017 Narayanan . .. .. .. C07C 255 /60 2005 /0101657 A1 5 /2005 Furuya et al . (73 ) Assignee : University of Tennessee Research 2007 /0265290 A1 11/ 2007 Dalton et al . 2010 /0227846 AL 9 /2010 Ito et al. Foundation , Knoxville , TN ( US ) 2014 / 0018433 A11 / 2014 Dalton et al . ( * ) Notice : Subject to any disclaimer , the term of this 2018 /0118663 A1 * 5 / 2018 Narayanan . C07C 237/ 20 patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U . S .
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Metabolic Enzyme/Protease
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Metabolic Enzyme/Protease Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. In each pathway, enzymes catalyze the conversion of substrates into structurally similar products. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation. Metabolism maintains the living state of the cells and the organism. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. Proteases can not only activate proteins such as cytokines, or inactivate them such as numerous repair proteins during apoptosis, but also expose cryptic sites, such as occurs with β-secretase during amyloid precursor protein processing, shed various transmembrane proteins such as occurs with metalloproteases and cysteine proteases, or convert receptor agonists into antagonists and vice versa such as chemokine conversions carried out by metalloproteases, dipeptidyl peptidase IV and some cathepsins. In addition to the catalytic domains, a great number of proteases contain numerous additional domains or modules that substantially increase the complexity of their functions.
    [Show full text]
  • DHEA, the Most Abundant Steroid Hormone in the Body
    CHAPTER 50 DHEA, the most abundant steroid hormone in the body: inhibits glucose-6-phosphate dehydrogenase, inhibits the generation of NADPH, activates the pyruvate dehydrogenase complex and increases oxidative phosphorylation, increases oxidative stress, polarizes the immune system to M1/Th1, inhibits the pathway PI3K/Akt and decreases proliferation and increases apoptosis in cancer José de Felippe Junior DHEA: substance synthesized in the body with multiple actions – Plasma DHEA-sulphate declines from a peak at age maintain health, prevent diseases and help to heal them. JFJ 20, in both men and women. In men, DHEA-s ranges Warning: your adrenal gland is prohibited from making DHEA from 11 to 2.5 microM and in women from 6 to 1 mi- if you live in Brazil. Nonconformist medical doctors croM, from 20 to 80 years respectively (Labrie-1997). The DHEA biological actions involve multiple re- ceptors. DHEA binds to steroid/nuclear receptors (e.g. DHEA in United States of America is considered as a pregnane X receptor/steroid and xenobiotic receptor or food supplement, in Europe as a hormone that requires PXR/SXR), estrogen receptors alpha, beta (ER-alpha medical prescription (Samaras-2013) and in Brazil, for and ER-beta), androgen (AR), cellular membrane re- reasons unknown, it is prohibited the commercializa- ceptors and endothelial cells receptors (activating tion and prescription. G-receptor-coupled proteins – GPCR) (Webb-2006, in Dehydroepiandrosterone – DHEA – is produced in Teng-2015). cortical adrenal gland and activated by sulfation in the It was found in Japanese with over 100 years in- liver and target organs. DHEA is the steroid hormone crease in telomere length in leukocytes, increased adi- or steroid pre-hormone in the highest amount in the ponectin concentration along with normal levels of body: 72% of the total (Ebeling-1994, Traish-2011).
    [Show full text]